Spire Healthcare (LSE:SPI) published its half-year results while its board is backing a cash takeover. The figures show a Business whose private patient income is still growing, but whose NHS work fell sharply early in the year and pushed profit down. The question is how that NHS decline affected Spire's first half, and how the results sit alongside the board-backed offer.
An independent hospital group
Spire Healthcare is an independent private healthcare provider in the UK, operating 38 hospitals and more than 55 clinics across England, Wales and Scotland. It treats patients funded by private medical insurance, those paying for themselves and patients referred by the NHS, and it also runs a primary care business. Sir David Sloman became interim chief executive on 5 September 2026, succeeding Justin Ash, and Debbie White has succeeded Sir Ian Cheshire as chair. The shares trade on the Main Market of the London Stock Exchange.
The board-backed offer
On 5 September 2026, Spire's board backed a cash offer of 250p per share from Tulip UK Bidco, backed by funds managed by Toscafund, THCP Advisory and Ares Management. The offer values the shares at about £1,026.5 million on a fully diluted basis and the enterprise at £2,307.6 million. The bidder's valuation equates to 8.6 times adjusted EBITDA for 2025, according to the announcement. The announcement put the premium at 66.2% to the closing price on 13 May 2026, and 28.7% to the 12-month volume-weighted average price. The deal is structured as a scheme of arrangement and needs Shareholder approval, court sanction and FCA approval. Irrevocable undertakings covered 214.9 million shares, about 53.4% of the issued capital, and completion is expected in the fourth quarter of 2026 or the first quarter of 2027. Spire remains in an offer period, with a stream of dealing disclosures published.
Half-year results
On 30 September 2026, Spire reported Revenue of £792.7 million for the six months to 30 June, down 0.5% from £796.7 million. Private medical insurance revenue rose 3.1% to £355.4 million and self-pay revenue increased 4.4% to £179.8 million. Primary care revenue grew 8.1% to £72.1 million. NHS revenue, however, fell 10.8% to £223.0 million. The company reported that the NHS decline was 24.9% in the first quarter, easing to 3.2% in the second.
Profit fell more steeply than revenue. Adjusted EBITDA declined 16.0% to £112.4 million, adjusted operating profit fell 33.4% to £50.6 million and the group recorded an adjusted loss before tax of £2.6 million, against a profit of £23.8 million a year earlier. The statutory loss before tax was £14.8 million. Basic Earnings Per Share was negative 2.9p, and adjusted basic earnings per share negative 0.5p, compared with 1.6p and 4.1p. Net bank Debt was £337.8 million, and Leverage rose to 2.4 times adjusted EBITDA from 2.0 times. Adjusted free Cash Flow improved 35.3% to £20.7 million. No Interim Dividend was proposed. The final dividend for 2025, of 1.5p, was paid on 19 June 2026. The company still targets full-year adjusted EBITDA "broadly in line with FY25, as previously communicated".
Risks and points to watch
NHS referral volumes depend on commissioning decisions and funding, and the first-quarter fall shows how quickly they can change. Higher leverage leaves less financial flexibility. For shareholders, the key uncertainties concern the offer: approvals, court sanction and timing. If the deal did not complete, the shares would again be valued on standalone performance, which this half shows was under pressure.
Conclusion
Spire's first-half profit fell because a sharp drop in NHS revenue, concentrated in the first quarter, outweighed growth in insured, self-pay and primary care work. The results arrive while shareholders consider a board-backed 250p cash offer, with completion expected by early 2027 subject to approvals.






Please wait processing your request...